High-potency APIs refer to the substances that, at very low doses, cause a biological response. Traditionally, cytotoxic substances and sex hormones like estrogen are used as examples of HPAPIs. Compared to standard APIs, highly potent active pharmaceutical ingredients HP (high potency) APIs market are nonetheless effective at considerably lower dosage levels, but their potency poses unique handling issues.
Sizing and Forecast
The hp (high potency) apis market size has grown strongly in recent years. It will grow from $23.39 billion in 2023 to $25.5 billion in 2024 at a compound annual growth rate (CAGR) of 9.0%. The growth in the historic period can be attributed to increasing demand for oncology therapies, rising emphasis of pharmaceutical companies on manufacturing of hpapis, a rise in healthcare awareness and expenditure, strong economic growth in emerging markets and increasing government initiatives..
The hp (high potency) apis market size is expected to see strong growth in the next few years. It will grow to $36.38 billion in 2028 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to a rise in the number of cancer cases, growing focus on precision medicine and increasing ageing population will drive the growth. . Major trends in the forecast period include focus on strategies such as production facility expansion and mergers and acquisitions, focus on increasing investments to grow hpapi production, use of artificial intelligence (ai) in manufacturing apis, focus on green manufacturing and focus on launch of new, innovative products..
Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/hp-high-potency-api-global-market-report
Segmentation & Regional Insights
The hp (high potency) apis market covered in this report is segmented –
1) By Type: Innovative HPAPI, Generic HPAPI
2) By Synthesis Type: Synthetic HPAPI, Biotech HPAPI
3) By Therapeutic Application: Oncology, Hormonal Disorder, Glaucoma, Other Therapeutic Applications
North America was the largest region in the global HP (high potency) APIs market in 2023. Middle East is expected to be the fastest growing region in the HP (high potency) APIs market report during the forecast period. The regions covered in the hp (high potency) apis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2814&type=smp
Major Driver Impacting Market Growth
The rising number of cancer cases coupled with increasing sales of cancer drugs contributed to the growth of the HP (high potency) APIs market. The rising incidence of cancer is resulting in increasing R&D for anticancer drugs which in turn is propelling the demand for the market. According to the World Health Organization’s International Agency for Research on Cancer (IARC) report, the cancer burden is expected to increase by 29.5 million new cases and 16.4 million deaths by 2040, globally. Moreover, 70% of deaths from cancer occur in middle and low-income countries. Therefore, the growing incidence of cancer cases is projected to upsurge revenues for the HP (high potency) APIs market growth.
Key Industry Players
Major companies operating in the hp (high potency) apis market report are Merck KGaA, Pfizer, Inc, Thermo Fisher Scientific, Inc, Teva Pharmaceuticals, Lonza Group AG, Sanofi (EUROAPI), Corden Pharma International, Dr. Reddy’s Laboratories Ltd., Siegfried Holding AG, Novartis, Roche India, Arlak Biotech (India), Healthkind Labs Pvt. Ltd, Swisschem Healthcare Pvt. Ltd, Apikos Pharma, Kolaz Biotech, Cstone Pharma (China), Carsgen Therapeutics (China), Jw Therapeutics (China), Beigene(China), Takeda Pharmaceuticals (Japan), Astellas Pharma Inc (Japan), Otsuka Pharmaceutical Co, Ltd (Japan), Legend Biotech Co (China), Abbott Laboratories, Vectura Group (U.K), Corex Logistics, Dokumeds, Medpace, Labcorp, Almedis (Russia), Neuca, Farmacol, Polska Grupa Farmaceutyczna, Polpharma, Tzmo, Eli Lilly And Company, Bristol-Myers Squibb Company, Apotex, Gilead Sciences, Abbvie Inc, Hisun Usa Inc, Glaxosmithkline, Amega Biotech, Biomarin Pharmaceutical, Ferring Pharmaceuticals, Tikun Olam Cannbit, Wavelength Pharmaceuticals, Saudibio, Tabuk Pharmaceuticals, Cipla, Bayer, Adcock Ingram, Johnson & Johnson, Astrazeneca Pharmaceutical (Pty) Ltd, Eurolab, Ranbaxy (Sa) (Pty) Ltd.
The hp (high potency) apis market report table of contents includes:
1. Executive Summary
2. Market Characteristics
3. Market Trends And Strategies
4. Impact Of COVID-19
5. Market Size And Growth
6. Segmentation
7. Regional And Country Analysis
.
.
.
27. Competitive Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
